CASI Pharmaceuticals (CASIF) Common Equity (2020 - 2025)

CASI Pharmaceuticals has reported Common Equity for 6 years, with the latest figure at -$37.3 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 2114.15% year-over-year to -$37.3 million; the trailing twelve-month figure through Dec 2025 stood at -$37.3 million (down 2114.15% YoY), and the FY2025 full-year result was -$37.3 million, down 2114.15% from the prior year.
• Common Equity for Q4 2025 stood at -$37.3 million, down from -$28.6 million in the prior quarter.
• The five-year high for Common Equity was $32.2 billion in Q2 2023, with the low at -$8.1 billion in Q1 2025.
• Historically, Common Equity has averaged $2.7 billion across 5 years, with a median of $1.9 million in 2024.
• Annual changes were most pronounced in 2021 — Common Equity increased 3.63% — and 2025, when it sank 2114.15%.
• CASI Pharmaceuticals' Common Equity stood at $84.5 million in 2021, then slumped by 47.25% to $44.6 million in 2022, then tumbled by 45.79% to $24.2 million in 2023, then sank by 92.34% to $1.9 million in 2024, then slumped by 2114.15% to -$37.3 million in 2025.
• The last three Common Equity figures came in at -$37.3 million (Q4 2025), -$28.6 million (Q3 2025), and -$20.3 million (Q2 2025), per Business Quant data.